Novavax Surpasses Q4 Estimates and Lifts 2026 Revenue Forecast
Novavax delivered a robust fourth-quarter performance, exceeding analyst expectations with earnings per share of $0.11 against a projected -$0.49. Revenue soared to $147 million, a 67% year-over-year increase, far surpassing the $90.25 million consensus. The company reversed its fortunes, posting an $18 million net profit compared to an $81 million loss in the prior year.
Cost-cutting measures and licensing deals, including a $530 million agreement with Pfizer for its Matrix-M adjuvant, fueled the turnaround. Novavax raised its 2026 adjusted revenue guidance to $230–$270 million, up from $185–$205 million, signaling confidence in its growth trajectory.
The stock closed at $9.53, reflecting a 35.18% gain over three months and a 34.99% rise year-to-date. Investors are closely watching the company's strategic moves as it capitalizes on its vaccine technology and partnerships.
